FY2026 EPS Estimates for Compugen Raised by HC Wainwright

Key Points

• HC Wainwright raised Compugen’s FY2026 EPS estimate to a loss of $0.35 per share from a prior forecasted loss of $0.38, while maintaining a “Buy” rating.
• Compugen reported a quarterly loss of $0.07 per share, beating the $0.08 consensus loss estimate, and generated $2.60 million in revenue versus expectations of $1.28 million.
• Analyst sentiment is mixed but leans positive, with the stock carrying a “Moderate Buy” consensus rating and an average price target of $5.00, compared with a recent price of $2.28.

Compugen Ltd. (NASDAQ:CGEN - Free Report) - Equities researchers at HC Wainwright upped their FY2026 earnings per share estimates for shares of Compugen in a research report issued on Tuesday, August 4th. HC Wainwright analyst S. Ramakanth now forecasts that the biotechnology company will earn ($0.35) per share for the year, up from their prior estimate of ($0.38). HC Wainwright currently has a "Buy" rating on the stock. The consensus estimate for Compugen's current full-year earnings is ($0.28) per share. HC Wainwright also issued estimates for Compugen's Q3 2027 earnings at ($0.10) EPS, Q4 2027 earnings at ($0.10) EPS, FY2027 earnings at ($0.41) EPS, FY2028 earnings at ($0.43) EPS, FY2029 earnings at ($0.44) EPS and FY2030 earnings at ($0.29) EPS.

Compugen (NASDAQ:CGEN - Get Free Report) last issued its quarterly earnings data on Monday, August 3rd. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.08) by $0.01. The firm had revenue of $2.60 million during the quarter, compared to the consensus estimate of $1.28 million. Compugen had a return on equity of 42.57% and a net margin of 47.56%.During the same period last year, the company earned ($0.08) EPS.

Other equities research analysts have also recently issued reports about the stock. Wall Street Zen cut shares of Compugen from a "buy" rating to a "hold" rating in a research report on Saturday, May 23rd. Leerink Partners decreased their price objective on shares of Compugen from $13.00 to $5.00 and set an "outperform" rating on the stock in a report on Thursday, May 21st. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Compugen in a research report on Friday, July 17th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $5.00.

Compugen Price Performance

NASDAQ CGEN opened at $2.28 on Thursday. The stock has a market capitalization of $215.58 million, a P/E ratio of 6.00 and a beta of 2.77. The firm's 50-day moving average is $2.24 and its two-hundred day moving average is $2.27. Compugen has a 12 month low of $1.29 and a 12 month high of $3.23.

Hedge Funds Weigh In On Compugen

A number of hedge funds and other institutional investors have recently bought and sold shares of CGEN. Bank Hapoalim BM acquired a new position in Compugen in the 4th quarter valued at about $37,000. Security National Bank of Sioux City Iowa IA acquired a new stake in shares of Compugen during the fourth quarter worth about $38,000. Calamos Advisors LLC purchased a new position in shares of Compugen in the first quarter valued at approximately $63,000. Franklin Resources Inc. purchased a new position in shares of Compugen in the second quarter valued at approximately $56,000. Finally, Hillsdale Investment Management Inc. acquired a new position in shares of Compugen in the first quarter valued at approximately $68,000. 12.22% of the stock is currently owned by hedge funds and other institutional investors.

About Compugen

Compugen Ltd. NASDAQ: CGEN is a clinical-stage therapeutic discovery company that leverages proprietary computational discovery platforms to identify novel immuno-oncology targets and biomarkers. The company combines large-scale biological datasets with machine learning algorithms to generate and validate new therapeutic and diagnostic candidates. Founded in 1993 and headquartered in Tel Aviv, Israel, Compugen also maintains a presence in the United States to support its clinical development and commercial collaborations.

Compugen's predictive discovery engine scans complex biological systems in silico to reveal previously unrecognized pathways and immune checkpoints involved in cancer progression.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source